Ionis Pharmaceuticals (IONS) Non Operating Investment Income (2009 - 2026)

Ionis Pharmaceuticals' Non Operating Investment Income history runs 15 years deep, the most recent figure standing at -$10.2 million for Q2 2026.

• In Q2 2026, Non Operating Investment Income rose 44.4% year-over-year to -$10.2 million; the TTM figure through Jun 2026 stood at $43.1 million (up 294.44% YoY), while the FY2025 annual figure was $10.2 million, up 453.76% from the prior year.
• Non Operating Investment Income for Q2 2026 stood at -$10.2 million, down from $22.6 million in the prior quarter.
• The five-year high for Non Operating Investment Income was $29.9 million in Q3 2025, with the low at -$18.3 million in Q2 2025.
• The 5-year median for Non Operating Investment Income is -$345000.0 (2023), against an average of $582500.0.
• The sharpest annual moves came in 2024 and 2025: Non Operating Investment Income slumped 1495.03% in 2024, then jumped 3302.5% in 2025.
• Ionis Pharmaceuticals' Non Operating Investment Income stood at $3.3 million in 2022, then tumbled by 104.9% to -$161000.0 in 2023, then plunged by 1495.03% to -$2.6 million in 2024, then soared by 130.69% to $788000.0 in 2025, then slumped by 1392.13% to -$10.2 million in 2026.
• Business Quant data shows IONS's Non Operating Investment Income at -$10.2 million in Q2 2026, $22.6 million in Q1 2026, and $788000.0 in Q4 2025.